Blank, Patricia R. and Moch, Holger and Szucs, Thomas D. and Schwenkglenks, Matthias. (2011) KRAS and BRAF mutation analysis in metastatic colorectal cancer : a cost-effectiveness analysis from a Swiss perspective. Clinical cancer research, Vol. 17, no. 19. pp. 6338-6346.
Full text not available from this repository.
Official URL: http://edoc.unibas.ch/dok/A6005410
Downloads: Statistics Overview
Abstract
Monoclonal antibodies against the epidermal growth factor receptor (EGFR), such as cetuximab, have led to significant clinical benefits for metastatic colorectal cancer (mCRC) patients but have also increased treatment costs considerably. Recent evidence associates KRAS and BRAF mutations with resistance to EGFR antibodies. We assessed the cost-effectiveness of predictive testing for KRAS and BRAF mutations, prior to cetuximab treatment of chemorefractory mCRC patients.
| Faculties and Departments: | 03 Faculty of Medicine > Departement Public Health > Pharmazeutische Medizin ECPM > Pharmazeutische Medizin (Szucs) |
|---|---|
| UniBasel Contributors: | Schwenkglenks, Matthias and Blank, Patricia R. |
| Item Type: | Article, refereed |
| Article Subtype: | Research Article |
| Publisher: | American Association for Cancer Research |
| ISSN: | 1078-0432 |
| Note: | Publication type according to Uni Basel Research Database: Journal article |
| Identification Number: | |
| Last Modified: | 13 Sep 2013 07:59 |
| Deposited On: | 13 Sep 2013 07:48 |
Repository Staff Only: item control page